Oncology and Hematology

Unlike other therapeutic areas, oncology trials are more sensitive in nature and require specific clinical expertise to properly manage. Although many barriers or reasons for failure can’t be predicted, with Clinipace Worldwide, you can lay the groundwork — including a solid study design, an experienced team, and the right technology — that will position your development program for success.

Eliminate barriers and increase participation rates
Low participation rates are a major bottleneck in developing new cancer treatments. A key factor in progress toward better treatment and prognosis in oncology lies in improving participation rates. We will help you improve those rates through the use of adaptive and simplified trial design, molecular profiling, patient-centric enrollment, and communication and education.

Take your oncology trials global
Approximately one-third of new cancer cases worldwide were diagnosed in select countries in South, East, and Southeast Asia. With centralized North American, South American, European, and Asian hubs, we can help navigate the nuances of local regulatory and contracting processes and relationships across countries in multinational trials.

When managed properly, effective oncology trials can save lives, generate new revenue streams and make breakthrough discoveries in a challenging therapeutic area. At Clinipace, we have the experience and expertise to guide you successfully through a wide range of multi-phase global oncology and hematology clinical trials.

Oncology Solid Tumor Experience
  • More than 150 clinical trials since 2010
  • Full program management
  • Phase 1 – 4 clinical trials
  • Management of successful, global pivotal studies
  • IND and CTA submissions
  • ISS/ISE and eCTD
  • Medical oncologists in North America, Europe and Latin America
  • Adaptive designs
  • Reformulations and 505(b)2 projects
Oncology Supportive Care Experience
  • Phase 1 – 4 clinical trials
  • Successful pivotal studies
  • IND and CTA submissions
  • Manuscripts
  • ISS/ISE, eCTD and MAA
  • Biosimilar experience
  • More than 262 sites
  • More than 3,000 subjects
  • More than 51 total projects
Oncology Hematologic Tumors Experience
  • More than 40 studies since 2010
  • Full program management
  • Phase 1 – 4 clinical trials
  • Management of global pivotal studies
  • IND and CTA submissions
  • ISS/ISE and eCTD
  • Extensive cell therapy experience
Immuno-oncology Experience
  • Phase 1 – 4 clinical trials
  • IND/CTA, IMPD, and IB development
  • ISS/ISE and eCTD
  • 44 projects
  • 568 sites & 4,280 subjects
  • Experience with:
    • Autologous & allogeneic vaccines
    • Biologics
    • Cell therapies
    • Cytokines
    • Immunostimulators

Interested in Oncology or Hematology?

Let's Chat